Fox Run Management, L.L.C. Ligand Pharmaceuticals Inc Transaction History

Fox Run Management, L.L.C.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 31, 2020	SELL	$68.28 - $123.65 $229,625 - $415,834	-3,363 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$63.37 - $107.88 $213,113 - $362,800	3,363 New	3,363 $245,000
Q1 2019 Oct 17, 2019	SELL	$105.93 - $142.47 $318,531 - $428,407	-3,007 Closed	0 $0
Q4 2018 Jan 15, 2019	BUY	$128.36 - $272.13 $385,978 - $818,294	3,007 New	3,007 $408,000
Q4 2017 Jan 18, 2018	SELL	$128.36 - $147.04 $243,884 - $279,376	-1,900 Closed	0 $0
Q3 2017 Oct 23, 2017	BUY	$120.91 - $137.94 $229,729 - $262,086	1,900	1,900 $259,000

262

18M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.94B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.